Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials
Serge Gauthier,1 Sandra Schlaefke2 1Alzheimer Disease Research Unit, Memory Clinic, McGill Centre for Studies in Aging, McGill University, Verdun, QC, Canada; 2Clinical Research Department, Dr Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany Abstract: The objective of t...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2014
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/9c26905708ca4e0396edca45419bbeca |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:9c26905708ca4e0396edca45419bbeca |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:9c26905708ca4e0396edca45419bbeca2021-12-02T06:57:26ZEfficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials1178-1998https://doaj.org/article/9c26905708ca4e0396edca45419bbeca2014-11-01T00:00:00Zhttps://www.dovepress.com/efficacy-and-tolerability-of-ginkgo-biloba-extract-egb-761reg-in-demen-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Serge Gauthier,1 Sandra Schlaefke2 1Alzheimer Disease Research Unit, Memory Clinic, McGill Centre for Studies in Aging, McGill University, Verdun, QC, Canada; 2Clinical Research Department, Dr Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany Abstract: The objective of this systematic review was to evaluate current evidence for the efficacy of Ginkgo biloba extract EGb 761® in dementia. Seven of 15 randomized, placebo-controlled trials in patients with dementia identified by database searches met all our selection criteria and were included in the meta-analysis. In these trials, patients were treated with 120 mg or 240 mg per day of the defined extract EGb 761 or placebo. Efficacy was assessed using validated tests and rating scales for the cognitive domain, the functional domain (activities of daily living), and global assessment. Tolerability was evaluated by risk differences based on incidences of adverse events and premature discontinuation rates. Of 2,684 outpatients randomized to receive treatment for 22–26 weeks, 2,625 represented the full analysis sets (1,396 for EGb 761 and 1,229 for placebo). Standardized mean differences for change in cognition (-0.52; 95% confidence interval [CI] -0.98, -0.05; P=0.03), activities of daily living (-0.44; 95% CI -0.68, -0.19; P<0.001), and global rating (-0.52; 95% CI -0.92, -0.12; P=0.01) significantly favored EGb 761 compared with placebo. Statistically significant superiority of EGb 761 over placebo was confirmed by responder analyses as well as for patients suffering from dementia with neuropsychiatric symptoms. Treatment-associated risks in terms of relative risks of adverse events and premature withdrawal rates did not differ noticeably between the two treatment groups. In conclusion, meta-analyses confirmed the efficacy and good tolerability of Ginkgo biloba extract EGb 761 in patients with dementia. Keywords: Alzheimer’s disease, vascular dementia, mixed dementia, efficacy, safetyGauthier SSchlaefke SDove Medical PressarticleAlzheimer's diseasevascular dementiamixed dementiaefficacysafetyGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 9, Pp 2065-2077 (2014) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Alzheimer's disease vascular dementia mixed dementia efficacy safety Geriatrics RC952-954.6 |
| spellingShingle |
Alzheimer's disease vascular dementia mixed dementia efficacy safety Geriatrics RC952-954.6 Gauthier S Schlaefke S Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials |
| description |
Serge Gauthier,1 Sandra Schlaefke2 1Alzheimer Disease Research Unit, Memory Clinic, McGill Centre for Studies in Aging, McGill University, Verdun, QC, Canada; 2Clinical Research Department, Dr Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany Abstract: The objective of this systematic review was to evaluate current evidence for the efficacy of Ginkgo biloba extract EGb 761® in dementia. Seven of 15 randomized, placebo-controlled trials in patients with dementia identified by database searches met all our selection criteria and were included in the meta-analysis. In these trials, patients were treated with 120 mg or 240 mg per day of the defined extract EGb 761 or placebo. Efficacy was assessed using validated tests and rating scales for the cognitive domain, the functional domain (activities of daily living), and global assessment. Tolerability was evaluated by risk differences based on incidences of adverse events and premature discontinuation rates. Of 2,684 outpatients randomized to receive treatment for 22–26 weeks, 2,625 represented the full analysis sets (1,396 for EGb 761 and 1,229 for placebo). Standardized mean differences for change in cognition (-0.52; 95% confidence interval [CI] -0.98, -0.05; P=0.03), activities of daily living (-0.44; 95% CI -0.68, -0.19; P<0.001), and global rating (-0.52; 95% CI -0.92, -0.12; P=0.01) significantly favored EGb 761 compared with placebo. Statistically significant superiority of EGb 761 over placebo was confirmed by responder analyses as well as for patients suffering from dementia with neuropsychiatric symptoms. Treatment-associated risks in terms of relative risks of adverse events and premature withdrawal rates did not differ noticeably between the two treatment groups. In conclusion, meta-analyses confirmed the efficacy and good tolerability of Ginkgo biloba extract EGb 761 in patients with dementia. Keywords: Alzheimer’s disease, vascular dementia, mixed dementia, efficacy, safety |
| format |
article |
| author |
Gauthier S Schlaefke S |
| author_facet |
Gauthier S Schlaefke S |
| author_sort |
Gauthier S |
| title |
Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials |
| title_short |
Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials |
| title_full |
Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials |
| title_fullStr |
Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials |
| title_full_unstemmed |
Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials |
| title_sort |
efficacy and tolerability of ginkgo biloba extract egb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials |
| publisher |
Dove Medical Press |
| publishDate |
2014 |
| url |
https://doaj.org/article/9c26905708ca4e0396edca45419bbeca |
| work_keys_str_mv |
AT gauthiers efficacyandtolerabilityofginkgobilobaextractegb761regindementiaasystematicreviewandmetaanalysisofrandomizedplacebocontrolledtrials AT schlaefkes efficacyandtolerabilityofginkgobilobaextractegb761regindementiaasystematicreviewandmetaanalysisofrandomizedplacebocontrolledtrials |
| _version_ |
1718399650338177024 |